Google
MDXG 株価分析 — Mimedx Group Inc (Healthcare >> Biotechnology)
MDXG に関するよくある質問
MDXGのPER（株価収益率）は？
Mimedx Group Inc（MDXG）は現在PER 19.49倍で取引されています。
MDXGのROE（自己資本利益率）は？
Mimedx Group IncのROEは2.89%です。
MDXGの配当利回りは？
Mimedx Group Incの配当利回りは0.00%です。
MDXGの品質スコア（Quality Score）は？
当社のAIはMDXGの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
MDXGは今が買い時ですか？
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
MDXGはどのセクターに属しますか？
Mimedx Group IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
MDXG AI Analysis Summary
Our AI summary for MDXG: Mimedx Group Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 19.49, ROE of 2.89%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 4.13
Price
-0.14
(-3.28%)
Day Change
|
|
|---|
MDXG, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
667
|
| Magic Formula Rank by ROE |
667
|
| Magic Formula Rank by ROIC |
533
|
| Price | 4.13 |
| PBV / Sector |
2.88 / 5.20
|
| Earning Per Share | 0.04 |
| PE / Sector |
19.49 / 19.97
|
| PEG or PE/Growth / Sector |
-0.20 / 1.22
|
| Average 1M Daily Value |
5.95 M
GREAT
|
| Average 1W Daily Value |
10.71 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:09 |
| Symbol | MDXG |
| Name | MIMEDX GROUP INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 145.76 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 622.40 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1775 West Oak Commons Court, NE, Marietta, GA, United States, 30062
Phone: 770 651 9100
Website: https://www.mimedx.com
Employees: 808
Sector: Healthcare >> Biotechnology
Description: MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
